Can Mounjaro Cause Nosebleeds? What Patients Ask Us

Are nosebleeds a recognised side effect of Mounjaro?

The short answer is no, not as a listed, recognised side effect. Mounjaro's Summary of Product Characteristics, which is the authoritative document governing how the medicine is prescribed in the UK, categorises side effects by frequency. The well-established ones are gastrointestinal: nausea, vomiting, diarrhoea, constipation, reflux and bloating are the most commonly reported, usually peaking around a dose start or increase before settling. Nosebleed, or epistaxis in clinical language, is not among them.

That absence matters. The SURMOUNT clinical programme enrolled thousands of adults with obesity over periods of up to 72 weeks, a large, closely monitored dataset. If nosebleeds had emerged as a meaningful pattern, they would appear in the trial reporting and subsequent prescribing guidance. They have not done so at the time of writing.

That said, absence from the listed profile does not mean a thing cannot happen. Rare, idiosyncratic reactions occur with any medicine. If you are experiencing nosebleeds since starting tirzepatide and want to understand more about whether Mounjaro might be involved, the most reliable step is a conversation with a prescriber who knows your full medical picture, rather than working from general information alone.

Why might some people notice nasal symptoms on tirzepatide?

There are plausible, indirect reasons why some people on Mounjaro notice nasal symptoms, though none amount to confirmed causal links. First, GLP-1 receptor agonists slow gastric emptying, which can worsen acid reflux in some patients. Reflux-related irritation occasionally extends to the upper airway and nasal passages, making the mucosal lining more vulnerable to minor trauma. Second, some people report reduced appetite for fluids early in treatment. Even mild dehydration dries out mucous membranes, including the nasal lining, and a fragile nasal membrane bleeds more readily from ordinary triggers, cold air, dry indoor heating, nose-blowing.

Neither of these explanations appears in the Mounjaro prescribing information as a documented mechanism; they are plausible indirect pathways that patients and clinicians discuss. If you are also experiencing a runny nose or nasal congestion alongside occasional bleeding, that fuller picture is worth describing to your prescriber, since it may point toward a seasonal or environmental cause rather than a medication effect.

Worth staying on top of hydration, particularly in winter when central heating is running. A dry house is a predictable trigger for nasal fragility regardless of any medicine.

When should you contact your prescriber or seek urgent help?

A single, brief nosebleed that stops quickly and has a clear cause (dry air, a knock, a cold) is unlikely to need urgent medical attention. The threshold changes when nosebleeds are frequent, last longer than 20 minutes despite standard first-aid measures (leaning forward, pinching the soft part of the nose), are very heavy, or have appeared without an obvious trigger since starting treatment.

If any of those describe your situation, speak to your GP or call 111. Do not stop taking Mounjaro without talking to your prescriber first, stopping a prescribed medicine abruptly is rarely the right move, and the two things may not be related at all. Your prescriber can review whether tirzepatide is the likely cause, whether another factor is more plausible, and whether any change to your treatment plan is warranted.

Separately, if you take anticoagulants (blood-thinning medicines such as warfarin or apixaban) or antiplatelet drugs and are considering Mounjaro, bleeding considerations including nosebleeds deserve careful prescriber review before treatment starts. GLP-1 medicines can affect how quickly the stomach processes other oral medicines, which has implications for drugs with narrow therapeutic windows.

How does reporting suspected side effects help everyone?

The UK's pharmacovigilance system depends on patients and clinicians reporting things they notice, even when the link is uncertain. Mounjaro carries a Black Triangle (▼) designation, meaning the MHRA is actively collecting safety data on it as a relatively new medicine. That status makes individual reports particularly valuable.

If you believe nosebleeds are connected to your treatment, submitting a Yellow Card report to the MHRA takes a few minutes and contributes to the evidence base that informs future prescribing guidance. You do not need to be certain of the link, suspicion is enough. You can report on behalf of yourself or someone else.

For wider questions about what Mounjaro does and how it works in the body, the full Mounjaro guide covers the mechanism, the evidence and the licensed eligibility criteria in detail. If cost is a factor in your thinking, our page on Mounjaro pricing in the UK sets out what an honest private-prescription price includes. And if you are ready to find out whether treatment is suitable for you, a prescriber from the nume clinical team can review your consultation the same day, not an algorithm, a named clinician.